Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.
作者信息
Lin Li
机构信息
Key laboratory of cellular physiology, Shanxi Medical University, China.
出版信息
Clin Med Pathol. 2008;1:83-91. doi: 10.4137/cpath.s667. Epub 2008 Jul 28.
Abstract
摘要
相似文献
1
Commonality between diabetes and Alzheimer's disease and a new strategy for the therapy.
Clin Med Pathol. 2008;1:83-91. doi: 10.4137/cpath.s667. Epub 2008 Jul 28.
2
Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.
Expert Opin Investig Drugs. 2019 Jan;28(1):93-97. doi: 10.1080/13543784.2019.1552677. Epub 2018 Dec 1.
3
[Alzheimer's disease and diabetes - the common pathogenesis].
Neuropsychopharmacol Hung. 2016 Mar;18(1):5-19.
4
[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.
5
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
Eur J Pharmacol. 2010 Mar 25;630(1-3):158-62. doi: 10.1016/j.ejphar.2009.12.023. Epub 2009 Dec 24.
6
Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation.
Neuroscience. 2014 Jan 3;256:137-46. doi: 10.1016/j.neuroscience.2013.10.038. Epub 2013 Oct 30.
7
Bariatric surgery may reduce the risk of Alzheimer's diseases through GLP-1 mediated neuroprotective effects.
Med Hypotheses. 2017 Jul;104:4-9. doi: 10.1016/j.mehy.2017.05.002. Epub 2017 May 3.
8
New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases.
Neural Regen Res. 2014 Nov 1;9(21):1870-3. doi: 10.4103/1673-5374.145342.
9
The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.
FEBS J. 2007 Aug;274(15):3775-83. doi: 10.1111/j.1742-4658.2007.05918.x. Epub 2007 Jul 6.
10
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease.
Neuropharmacology. 2018 Jun;135:48-62. doi: 10.1016/j.neuropharm.2018.02.027. Epub 2018 Feb 28.
引用本文的文献
1
The Role of Heme and Copper in Alzheimer's Disease and Type 2 Diabetes Mellitus.
JACS Au. 2023 Feb 17;3(3):657-681. doi: 10.1021/jacsau.2c00572. eCollection 2023 Mar 27.
2
Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.
Int J Mol Sci. 2023 Feb 7;24(4):3325. doi: 10.3390/ijms24043325.
3
Association of impaired fasting glucose and Type 2 Diabetes Mellitus with brain volume changes in Alzheimer's Disease patients analyzed by MRI: a retrospective study.
PeerJ. 2020 Aug 27;8:e9801. doi: 10.7717/peerj.9801. eCollection 2020.
4
Therapeutic Potential of Genipin in Central Neurodegenerative Diseases.
CNS Drugs. 2016 Oct;30(10):889-97. doi: 10.1007/s40263-016-0369-9.
5
Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy.
Neurochem Res. 2016 Jun;41(6):1475-82. doi: 10.1007/s11064-016-1859-3. Epub 2016 Feb 17.
6
Geniposide prevents rotenone-induced apoptosis in primary cultured neurons.
Neural Regen Res. 2015 Oct;10(10):1617-21. doi: 10.4103/1673-5374.167760.
本文引用的文献
1
Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture.
Endocrine. 1995 Jul;3(7):499-503. doi: 10.1007/BF02738824.
2
Common pathological processes in Alzheimer disease and type 2 diabetes: a review.
Brain Res Rev. 2007 Dec;56(2):384-402. doi: 10.1016/j.brainresrev.2007.09.001. Epub 2007 Sep 11.
3
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
Exp Neurol. 2007 Feb;203(2):293-301. doi: 10.1016/j.expneurol.2006.09.028. Epub 2006 Nov 22.
4
Alois Alzheimer and Alzheimer's disease: a centennial perspective.
J Neurochem. 2006 Nov;99(3):708-10. doi: 10.1111/j.1471-4159.2006.04212.x.
5
Disease modifying therapy for AD?
J Neurochem. 2006 Nov;99(3):689-707. doi: 10.1111/j.1471-4159.2006.04211.x.
6
Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Biochem Pharmacol. 2007 Jan 1;73(1):84-93. doi: 10.1016/j.bcp.2006.09.013. Epub 2006 Sep 17.
7
Nutrient regulation of pancreatic beta-cell function in diabetes: problems and potential solutions.
Biochem Soc Trans. 2006 Nov;34(Pt 5):774-8. doi: 10.1042/BST0340774.
8
Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes.
Cardiovasc Diabetol. 2006 Oct 4;5:21. doi: 10.1186/1475-2840-5-21.
9
Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides.
Bioorg Med Chem. 2006 Dec 15;14(24):8210-8. doi: 10.1016/j.bmc.2006.09.021. Epub 2006 Sep 28.
10
GLP-1 and type 2 diabetes: physiology and new clinical advances.
Curr Opin Pharmacol. 2006 Dec;6(6):598-605. doi: 10.1016/j.coph.2006.08.003. Epub 2006 Sep 20.
Zotero 插件